Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States — Shaji Kumar (2020) | RDL Network
Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States
Article 2020 en
Authors
SK
Shaji Kumar
IM
István Májer
SP
Sumeet Panjabi
Abstract
1 min read
When compared with Kd27 BIW, Kd70 QW is the optimal dose that represents a cost-effective utilization of health care budget with incremental CE ratios well below the accepted willingness-to-pay thresholds in the US.
Philippe Moreau, A. Keith Stewart, Meletios A Dimopoulos, David S. Siegel, Thierry Façon, James Berenson, Noopur Raje, Jesús G. Berdeja, Robert Z. Orlowski, Hui Yang, Haijun Ma, Zandra Klippel, Anita Zahlten‐Kumeli, Khalid Mezzi, Karim Iskander, M.‐V. Mateos
Philippe Moreau, A. Keith Stewart, Meletios A Dimopoulos, David S. Siegel, Thierry Façon, James R. Berenson, Noopur Raje, Jesús G. Berdeja, Robert Z. Orlowski, Hui Yang, Haijun Ma, Zandra Klippel, Anita Zahlten‐Kumeli, Khalid Mezzi, Karim Iskander, María‐Victoria Mateos
Thierry Façon, Rubén Niesvizky, María‐Victoria Mateos, David S. Siegel, Cara A. Rosenbaum, Sara Bringhen, Katja Weisel, P. Joy Ho, Heinz Ludwig, Shaji Kumar, Kenneth T. Wang, Mihaela Obreja, Zhao Yang, Zandra Klippel, Khalid Mezzi, Amanda Goldrick, Christina Tekle, Meletios A Dimopoulos
Discussion(0)
No comments yet. Be the first to comment.